Empagliflozin → AMPK → pancreatic ductal adenocarcinoma

• Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway

  A→B
  J Am Heart Assoc· 2025· PMID 40767292· doi
• A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction

  B→C
  Adv Sci (Weinh)· 2024· PMID 38885414· doi
• Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation

  A→B
  Int J Mol Sci· 2023· PMID 37373164· doi
• Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway

  A→B
  Front Physiol· 2022· PMID 35299662· doi
• Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis

  A→B
  Antioxidants (Basel)· 2022· PMID 36358524· doi
• Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice

  A→B
  Int J Biol Sci· 2020· PMID 32015688· doi
• Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes

  A→B
  J Cell Biochem· 2018· PMID 30474134· doi
• Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission

  A→B
  Redox Biol· 2017· PMID 29306791· doi

Each row is one structured triple extracted by deepseek-v4-flash (prompt v1_2026_05_07, source: configured). Confidence is the LLM's self-rating.

• empagliflozinactivatesAMPKA→B
  "in diabetic myocardial microvascular injury"confidence 0.70· extraction run #26· claim #164310
• EmpagliflozinactivatesAMPKA→B
  "in kidney and ileum of T2DM mice and HK-2 cells"confidence 0.90· extraction run #27· claim #169102
• EmpagliflozinupregulatesAMPKA→B
  "in liver of thioacetamide-treated rats"confidence 0.90· extraction run #27· claim #176036
• empagliflozinactivatesAMPKA→B
  "in db/db mice and HL7702 cells"confidence 0.85· extraction run #27· claim #180928
• empagliflozinactivatesAMPKA→B
  "in HFpEF mouse model and H9c2 cardiomyocytes"confidence 0.85· extraction run #27· claim #187327
• empagliflozinactivatesAMPKA→B
  "in liver of OLETF rats"confidence 0.80· extraction run #27· claim #190655
• EmpagliflozinactivatesAMPKA→B
  "in mice with chronic kidney disease on a high-phosphate diet"confidence 0.80· extraction run #27· claim #204545
• AMPKassociated_withpancreatic ductal adenocarcinomaB→C
  "in a subtype of PDAC"confidence 0.80· extraction run #17· claim #67189

No claims match this filter.

edge_support_log_ab

log(ab + 1) = 2.079

edge_support_log_bc

log(bc + 1) = 0.693

novelty_factor

1.000 (no direct drug→outcome evidence — full novelty)

direct_a_to_c_count

0

Embeddings are used at the L1 filtering stage to prune off-topic abstracts before claim extraction. They do not directly score the hypothesis.

model

bge-m3

dim

1024

max_length

8192 tokens

similarity_scores

No per-hypothesis cosine scores stored.

method

swanson_abc_log_evidence_with_novelty_penalty

formula

score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)

raw score

0.2773

outreach score

0.2773

quality tier

high